Enovis (NYSE:ENOV) Share Price Breaks Below 50 Day Moving Average - Here's What Happened

Key Points

• Enovis shares fell below their 50-day moving average, trading as low as $19.83 versus the $20.02 average, and last changing hands at $19.92 on volume of about 2.5 million shares.
• Analyst sentiment remains broadly positive: 10 analysts rate the stock a Buy, compared with one Hold and one Sell, producing a consensus “Moderate Buy” rating and an average price target of $37.25.
• Insiders purchased 23,293 shares worth approximately $449,599 over the past three months, while institutional investors own 98.45% of Enovis stock.

Enovis Corporation (NYSE:ENOV - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $20.02 and traded as low as $19.83. Enovis shares last traded at $19.92, with a volume of 2,524,526 shares.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ENOV shares. BMO Capital Markets set a $27.00 target price on Enovis in a report on Tuesday, September 1st. Weiss Ratings lowered Enovis from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, October 16th. Citigroup reissued a "market outperform" rating on shares of Enovis in a report on Wednesday, September 2nd. Evercore set a $32.00 price target on Enovis in a research report on Monday, July 6th. Finally, Wall Street Zen raised Enovis from a "hold" rating to a "buy" rating in a research note on Saturday. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $37.25.

Enovis Price Performance

The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The stock has a 50 day simple moving average of $20.02 and a 200-day simple moving average of $23.08. The firm has a market cap of $1.15 billion, a PE ratio of -1.03 and a beta of 1.37.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. The business had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The business's revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert bought 2,660 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The shares were bought at an average price of $18.80 per share, with a total value of $50,008.00. Following the purchase, the insider owned 63,898 shares of the company's stock, valued at $1,201,282.40. This trade represents a 4.34% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Damien Mcdonald purchased 13,035 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was acquired at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the acquisition, the chief executive officer owned 247,077 shares in the company, valued at $4,731,524.55. This represents a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 23,293 shares of company stock worth $449,599 in the last three months. 2.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enovis

Institutional investors and hedge funds have recently modified their holdings of the stock. Paradigm Capital Management Inc. NY boosted its stake in Enovis by 70.2% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock valued at $40,420,000 after buying an additional 732,917 shares during the last quarter. Private Management Group Inc. grew its holdings in Enovis by 38.8% during the 2nd quarter. Private Management Group Inc. now owns 1,365,082 shares of the company's stock valued at $28,257,000 after buying an additional 381,705 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Enovis by 38.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company's stock worth $24,430,000 after acquiring an additional 287,687 shares during the last quarter. Front Street Capital Management Inc. increased its stake in Enovis by 106.1% in the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company's stock worth $16,973,000 after acquiring an additional 384,124 shares during the last quarter. Finally, Quantinno Capital Management LP increased its stake in Enovis by 130.8% in the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company's stock worth $13,752,000 after acquiring an additional 342,556 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

About Enovis

Enovis Corporation NYSE: ENOV is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company's products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.